The Treat FTD Fund

The Treat FTD Fund supports clinical trials for frontotemporal degeneration through a joint ADDF-AFTD route. It sits at the clinical end of ADDF's FTD work and is built for teams that are already past early discovery and into patient-facing development. The program uses grant funding, runs annually, and is open globally to for-profit companies, nonprofits, universities, and research organizations. The award cap is $2.5 million. Because the funding is negotiated against milestone achievement and patient enrollment, the route behaves more like a structured development partnership than a simple research grant. The process is selective: review is handled by an FTD expert panel, and payments are tied to progress rather than paid as an unconditional lump sum. That makes the fund a strong fit for teams with a clear clinical protocol, an active recruitment path, and enough operational discipline to execute a trial. The practical emphasis is on measurable progress, not just a credible hypothesis.

Each grant below is a distinct funding opportunity with its own eligibility, scope, and deliverables.